One of the most common metabolic illnesses worldwide is the MetS. In the
MetS and its related disorders, rationalized and evidence-based pharmacotherapeutic
strategies are corner stones in the mitigation of polypharmacy. The pharmacology
network approach and enhanced bioinformatics tools related to the epigenetic,
genomic, transcriptomics, proteomic, and metabolomic levels are considered useful
bench-side tools for the exploration of molecular preventive and therapeutic
multitargets. Molecular multitarget therapy is regarded as a novel pharmacological
strategy that forms the foundation of personalized and precision medicine. That will
decrease the socioeconomic burden and will improve the health-related quality of life.
Keywords: Bioinformatic analysis, Gene Expression Omnibus (GEO) database, Hub genes, Insulin resistance, Metabolic syndrome, Mmolecular multi-target therapy, Next Generation Sequencing (NGS), Polypharmacy, Protein-Protein Interaction (PPI) network, Precision medicine, Personalized medicine, Pharmacology network, Receiver operating characteristic curve (ROC) analysis.
